M&A expertise for regmed

M&A expertise for regmed

19.12.2014 - Gil Beyen has been appointed independent director of Belgian biotech Novadip Biosciences, a spin-off from Louvain University and Saint-Luc University Hospital active in skeletal regenerative medicine.

Beyen is currently CEO and chairman of Erytech Pharma. Before that he served as CEO of French biotech Tigenix, which he also co-founded. In this capacity, he led the development and regulatory approval of ChondroCelect, the first Advanced Therapy Medicinal Product in Europe. He was also instrumental in the listing of the company and the subsequent merger with Cellerix. Beyen holds an MSc in Bio-Engineering from the University of Leuven and obtained an MBA from the University of Chicago in 1990.

28.08.2014 Long-time CEO of Santen Inc. Adrienne Graves has joined the Board of Directors at French ophthalmic company Nicox S.A.

© Nicox

In tandem with Luzi von Bidder and Les Kaplan, who are also freshly appointed to the Board, Graves will be replacing Vaughn Kailian and Vince Anido, who are both stepping down. Before taking on duties as President and CEO at Santen – the US arm of Japan's largest ophthalmic pharmaceutical company – Graves spent nine years with Alcon Laboratories, where her roles included that of Director of International Ophthal­mology. She currently serves as Director on several corporate boards, among them Akorn Inc., TearLab Corporation, Aerpio, Encore Vision and Envisia Therapeutic.

25.08.2014 Gene and cell therapy company Oxford Biomedica plc has appointed Paul Blake as Chief Development Officer.

© Oxford Biomedica

Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a Canada-based biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. Paul was a Member of the Board at Memory Pharmaceutical, Inc. and founding Board member of Protez Pharmaceuticals, which were later acquired by Roche and Novartis, respectively. He was also Director of ViaCell and held senior management positions at Cephalon Inc. He is a fellow of the Royal College of Physicians, a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and also a fellow of the American College of Clinical Pharmacology.

Effective September 1st, Blake will take over responsibility for the clinical development of Oxford Biomedica’s therapy pipeline. Blake will also remain a member of the company’s board, which he joined in early 2010.

22.08.2014 Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.


Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

21.08.2014 Swedish pharmaceutical company Medivir has a new president and CEO: board member Niklas Prager is succeeding Maris Hartmanis effective September 1st.

© Medivir

Prager has long experience of senior executive positions in trade and industry - both as CEO and as board member. He is currently chairman of the board of Qbtech AB and a member of the board of Egain Group AB. Before that, he was chairman of the boards of Biophausia AB, Envirotainer AB and Michael Berglund Search Group AB. He has also served as the CEO of Pfizer AB, Envirotainer AB and Qbtech AB. Stockholm-based Medivir expects a strong contribution to the company's strategic business development and commercialisation of its product portfolio. Prager commented: "An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way."

18.08.2014 Adrian Percy has taken over the position of Global Head of Research and Development at Bayer Cropscience and is also the newest member of the Excecutive Committee.

© Bayer Cropscience

Most recently, Percy was responsible for for regulatory affairs activities at Bayer Cropscience as Senior Vice President of Global Regulatory Affairs. Before that, he held numerous positions in the Research and Development departments of the German company and its legacy companies in France, Germany and the USA. He grew up and studied in the United Kingdom earning a Bachelor’s degree in Pharmacology at the University of Liverpool, a Master’s degree in Toxicology and then a doctorate in Biochemistry at the University of Birmingham. Percy succeeds David Nicholson, who has left the company.

14.08.2014 Matthew Pauls is taking over the leadership for Swedish biopharmaceutical company Cortendo AB. With his extensive pharma background and experience in commercial operations, Pauls aims to orient Cortendo toward product commercialisation.

Cortendo AB

Once Pauls has taken over the new role of president and CEO, erstwhile CEO Joseph Reiser will assume the position of chairman of the board. Current chairman Eigil Stray Spetalen will step down to assume a regular board position.

Before joining Cortendo, Pauls was Chief Commercial Officer of US biopharmaceutical company Insmed, Inc, and before that, he worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. Pauls also held positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various US and global commercial roles. Mr. Pauls holds BS and MBA degrees from Central Michigan University and a JD from Michigan State University College of Law.

07.08.2014 John P. Donoghue is taking over the management of the Geneva Wyss Center for Bio-and Neuro-engineering at Campus Biotech.

campus biotech

The internationally recognised neuroscientist was also appointed adjunct professor at the École Polytechnique Fédérale de Lausanne (EPFL) and visiting professor at the University of Geneva. Donoghue is the founder of Brown University’s Institute for Brain Science in Rhode Island, USA, and works as a professor of neuroscience and engineering at Brown University. He also holds the Henry Merritt Wriston chair. He will take a one year sabbatical from Brown in 2015 during which he will be devoted to his position as Head of the Wyss Center.

Donoghue is among the founding fathers of neuroprosthetics - the merger between neuroscience and cybernetics. He is best known for having developed innovative brain-computer interfaces for people with paralysis.

11.08.2014 Sir Alec Jeffreys has been awarded the Royal Society’s Copley Medal. The British geneticist received the medal for his pioneering work on variation and mutation in the human genome.

Jane Gitschier, PLoS Genetics

Jeffreys is well known for his 1984 discovery of a method to show the variation between individuals’ DNA, a technique which became known as genetic fingerprinting.  He made the discovery in his lab at the University of Leicester after looking at an X-ray image of the DNA of the different members of his lab technician’s family. Genetic fingerprinting has since been used to resolve issues of identity and kinship, becoming a formative method used in modern forensic science. Jeffreys continued working with this method, further refining it towards DNA profiling. “Sir Alec’s work has transformed our understanding of human genetics“, said Sir Paul Nurse, President of the Royal Society.

The Royal Society awards the Copley medal since 1731, making it the scientific prize believed to be the oldest in the world. It is awarded for outstanding achievements in scientific research. Before Jeffreys, scientists such as Charles Darwin, Michael Faraday, Albert Einstein and Stephen Hawking have been awarded.

04.08.2014 Former Merck & Co. president for Europe and Canada Bruno Strigini has been appointed president of Novartis Oncology.

Novartis Oncology

Right off the bat, Strigini’s career started off internationally, with an MBA from Swiss IMD, a doctorate degree in pharmacy from the French University of Montpellier, and a master's degree in microbiology from UK’s Heriot-Watt University. Since then, he has worked in pharmaceuticals, animal health, OTC and vaccines for 25 years. Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included President of International Operations, President of Japan and Asia-Pacific, and Senior Vice-President and Head of Global Marketing & Business Development, as well as Managing Director positions in New Zealand, the UK and Spain.

His expertise stretches across diverse geographies, including both mature and emerging markets. He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France.

29.07.2014 The UK government has named George Freeman, MP, as minister for life sciences. The position has been newly created and is aimed to bridge the departments of health and business.

George Freeman

Freeman has extensive background as a biotech venture capitalist. Before being elected to Parliament in 2010, he was Founder and Chairman of 4D Biomedical Ltd, a specialist translational medicine consultancy. Before that, he was CEO of Cambridge-based start-up Amedis Pharmaceuticals and Director of Early Stage Ventures at Merlin Biosciences.

Freeman served as Government Life Science Advisor from 2011 to 2013 to the Minister of State for Universities and Science. In this capacity, he supported the coordination of the Prime Minister's Life Science Strategy. He is involved in the UK Government department UK Trade & Investment (UKTI) to promote the UK Life Science sector including representing the UK Government on trade missions to the USA and Sweden.

Vorherige Seite3/22Nächste Seite

Product of the week



All Events

Current issue

All issues